Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.

Author: BirkenhägerTom K, BruijnJan A, MolemanPeter, MulderPaul G, van den BroekWalter W

Paper Details 
Original Abstract of the Article :
BACKGROUND: The aim of this study was to examine whether phenelzine is a suitable alternative to tranylcypromine in antidepressant-resistant depression. METHOD: A total of 77 severely depressed in-patients, meeting the DSM-IV criteria for major depressive disorder, who failed to respond to fixed pl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.4088/jcp.v65n1110

データ提供:米国国立医学図書館(NLM)

Efficacy and Tolerability of MAOIs in Antidepressant-Refractory Depression

Depression is a complex condition that can be as challenging to navigate as a vast desert. This study investigates the efficacy of two monoamine oxidase inhibitors (MAOIs), tranylcypromine and phenelzine, in treating antidepressant-refractory depression, a condition that often feels as desolate as a barren landscape. The study used a double-blind, flexible-dose design, a method as meticulous as a desert explorer meticulously planning their route, to compare the effectiveness of these two MAOIs in a group of 77 severely depressed patients who had not responded to conventional treatments.

No Significant Difference in Efficacy

The researchers found no significant differences in efficacy between the two MAOIs, suggesting that both medications could be effective options in treating severe, refractory depression. This finding is like discovering a hidden oasis in the heart of the desert, providing hope for those struggling with this challenging condition. The study also found that both medications were associated with similar rates of side effects, primarily dizziness, agitation, and insomnia, indicating that while these side effects may occur, they are manageable.

Phenelzine: A Potential Alternative to Tranylcypromine

The study's findings are significant in providing clinicians with a suitable alternative to tranylcypromine for treating antidepressant-refractory depression. This discovery is similar to finding a new path through a seemingly impassable desert, expanding the options for treating this complex condition.

Dr. Camel’s Conclusion

This research emphasizes that while depression can feel like an endless desert, there are effective treatment options available. The study offers hope for individuals battling severe, treatment-resistant depression by demonstrating the efficacy of MAOIs and offering a potential alternative to tranylcypromine.

Date :
  1. Date Completed 2004-12-21
  2. Date Revised 2019-09-02
Further Info :

Pubmed ID

15554763

DOI: Digital Object Identifier

10.4088/jcp.v65n1110

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.